Quent Capital’s Ocular Therapeutix OCUL Stock Holding History

Quent Capital’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.7K	Hold	410	–	–	﹤0.01%	1502
2026 Q2	$4.03K	Sell	410 -244	-37%	-$2.21K	﹤0.01%	1388
2026 Q1	$5.54K	Hold	654	–	–	﹤0.01%	1258
2025 Q4	$7.94K	Sell	654 -96	-13%	-$1.17K	﹤0.01%	1198
2025 Q3	$8.77K	Buy	+750	New	+$8.97K	﹤0.01%	1039
2025 Q2	–	Sell	-750	Closed	-$5.5K	–	944
2025 Q1	$5.5K	Hold	750	–	–	﹤0.01%	1001
2024 Q4	$6.4K	Hold	750	–	–	﹤0.01%	995
2024 Q3	$6.52K	Hold	750	–	–	﹤0.01%	1055
2024 Q2	$5.13K	Hold	750	–	–	﹤0.01%	1083
2024 Q1	$6.82K	Sell	750 -3	-0.4%	-$21	﹤0.01%	1071
2023 Q4	$3.36K	Buy	753 +108	+17%	+$319	﹤0.01%	1138
2023 Q3	$2.02K	Buy	645 +244	+61%	+$998	﹤0.01%	1175
2023 Q2	$2.07K	Buy	+401	New	+$2.38K	﹤0.01%	1182
2023 Q1	–	Sell	-490	Closed	-$1.38K	–	1338
2022 Q4	$1.38K	Buy	+490	New	+$1.62K	﹤0.01%	1190

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Summer Road West Palm Beach, Florida $135M AUM 15.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Deltec Asset Management New York $642M AUM 16.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Empire Life Investments Toronto, Ontario, Canada $1.83B AUM 33.18% 1-Year Est. Return

Peregrine Capital Management Minneapolis, Minnesota $2.95B AUM 28.43% 1-Year Est. Return

IMC Chicago Chicago, Illinois $483B AUM 41.26% 1-Year Est. Return

Quent Capital's OCUL Position: Q3 2026 in Review

Quent Capital held its Ocular Therapeutix (OCUL) position steady in Q3 2026 at 410 shares worth $2.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1502.

Quent Capital first reported a position in OCUL in Q4 2022 and has held it in 14 quarters since. The position peaked at $8.77K in Q3 2025. 113 funds tracked by Wall St. Rank hold OCUL as of Q3 2026.

Quent Capital held 410 shares of Ocular Therapeutix worth $2.7K as of Q3 2026.
Quent Capital left its Ocular Therapeutix share count unchanged in Q3 2026.
Ocular Therapeutix made up ﹤0.01% of Quent Capital's portfolio in Q3 2026, its #1502 holding.
Quent Capital first reported a position in Ocular Therapeutix in Q4 2022 and has held it in 14 quarters since.
Quent Capital's Ocular Therapeutix position peaked at $8.77K in Q3 2025.
113 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2026.

Based on Quent Capital's 13F filing for Q3 2026, filed 9 Nov 2026.